Evidence map›Paper›PMID 38940373›Full record

ArticleFuture oncology (London, England)2024

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.

Junsik Park, Hyun Woong Cho, Myong Cheol Lim, Chel Hun Choi, Jung-Yun Lee

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Mucin-Targeted Antibodies for Ovarian Cancer.Seminars in nuclear medicine · 2025
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junsik ParkDepartment of Obstetrics & Gynecology, Soonchunhayng University Bucheon Hospital, Soonchunhayng University College of Medicine, Bucheon, South Korea.ORCID 0000-0003-4094-2097
Hyun Woong ChoDepartment of Obstetrics & Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Myong Cheol LimCenter for Gynecologic Cancer, National Cancer Center, Goyang, South Korea.
Chel Hun ChoiDepartment of Obstetrics & Gynecology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
Jung-Yun LeeDepartment of Obstetrics & Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0001-7948-1350

Funding

CanariaBioNational Research Foundation of the Republic of Korea NRF-2021R1A2C1093502
6 · The paper itself

Abstract

A consensus regarding subsequent therapeutic strategies for patients with platinum- and poly (ADP-ribose) polymerase inhibitor (PARPi)-resistant ovarian cancer is lacking. These patients typically receive non-platinum-based chemotherapy; however, survival outcomes remain poor. Compared with chemotherapy alone, combination therapy with novel target agents can provide additional benefits to these patients. Oregovomab, an investigational murine monoclonal antibody against CA-125, has shown promising efficacy in a phase II study in patients with recurrent ovarian cancer. Herein, we described the rationale and design of OPERA/KGOG 3065/APGOT-OV6, a multicenter, investigator-initiated, two-cohort, single-arm phase II trial, aimed at examining the efficacy of oregovomab plus non-platinum-based chemotherapy in patients with PARPi/platinum-resistant ovarian cancer. The primary end point was the objective response rate, according to RECIST 1.1.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedClinical Trials, Phase II as TopicFemaleHumansMiddle AgedMulticenter Studies as TopicAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedoregovomabPoly(ADP-ribose) Polymerase InhibitorsAntibody anti-CA125indirect immunizationoregovomabovarian neoplasmsrecurrenceresistant

Identifiers

PMID38940373
PMCPMC11497973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.